Corvus Pharmaceuticals earnings were -$41.4M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest CRVS earnings report on Mar 31, 2025 announced Q1 2025 earnings of $15.2M, down 225.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CRVS reported annual earnings of -$62.3M, with 130.5% growth.
Corvus Pharmaceuticals Earnings Reports & History FAQ
What were Corvus Pharmaceuticals's earnings last quarter?
On CRVS's earnings call on Invalid Date, Corvus Pharmaceuticals (NASDAQ: CRVS) reported Q1 2025 earnings per share (EPS) of $0.21, up 275% year over year. Total CRVS earnings for the quarter were $15.19 million. In the same quarter last year, Corvus Pharmaceuticals's earnings per share (EPS) was -$0.12.
Is Corvus Pharmaceuticals profitable or losing money?
As of the last Corvus Pharmaceuticals earnings report, Corvus Pharmaceuticals is currently losing money. Corvus Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$41.40 million, a 66.55% increase year over year.
What was CRVS's earnings growth in the past year?
As of Corvus Pharmaceuticals's earnings date in Invalid Date, Corvus Pharmaceuticals's earnings has grown year over year. CRVS earnings in the past year totalled -$41.40 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.